Compounded Peptides ·
Multiple class action lawsuits filed through 2024 and 2025 allege that certain compounded semaglutide products did not contain labeled quantities of active ingredient, contained unidentified substances, or were marketed with deceptive claims. Plaintiffs' theories generally rely on state consumer protection statutes and state drug-purity laws rather than the FDCA, since the FDCA does not provide a private right of action. The 2026 dockets include putative class actions in federal court in the Northern District of California, the Southern District of New York, and the District of Minnesota. Several actions have survived motions to dismiss, opening the door to broader discovery into compounded peptide operations.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.